← All trials
NCT01026857
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 1, 2006
- Primary completion
- Apr 1, 2009
- Completion date
- Dec 1, 2009
- First posted
- —
- Last posted
- —
- Enrollment
- 121
- Arms / groups
- 3 / —
- Source
- AACT · pre-existing
Sponsors
- Leadiant Biosciences, Inc.Lead sponsor
- Luigi Sacco University HospitalOverall official - principal investigator
- Klinika Przewodu Pokarmowego Szpital Kliniczny Nr 1 - Lodz - PolandOverall official - principal investigator
- Vilnius UniversityOverall official - principal investigator
- Wojewodzki SzpitalOverall official - principal investigator
- University of Roma La SapienzaOverall official - principal investigator
- University of Naples Frederico IIOverall official - principal investigator
- Government of RussiaOverall official - principal investigator
- Kaunas UniversityOverall official - principal investigator
- Samodzielny Publiczny SzpitalOverall official - principal investigator
- Catholic University of Sacred Heart, RomeOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.